user_id,pmid_id,selection,annotation,outcome,comparator,intervention,invalid prompt,prompt reason
lidija,2875419,No significant difference,"Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254)", Weight Gain , detemir , glargine ,0,
lidija,2366143,Cannot tell based on the abstract,, cervical Bishop's score , placebo , antibiotic therapy ,0,
lidija,2366143,Invalid Prompt,,  cervical Bishop's score  ,  placebo  ,  antibiotic therapy  ,1, No data on cervical Bishop's score after therapy.
lidija,3281242,Significantly increased,"Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7–9.4; p < .0001) and through 24 weeks follow-up (Weeks 9–24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6–7.5; p < .0001).", continuous abstienence at 24 week follow up , placebo , varenicline ,0,
lidija,1764008,No significant difference,Differences in the duration of the active-first and the second stages of labor were not statistically significant., duration of labor stages , epidural analgesia , Meperidine analgesia ,0,
lidija,2875419,No significant difference,"27.5 and 25.6% of patients reached the primary outcome with glargine and detemir, respectively, demonstrating the noninferiority of glargine. Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), with similar proportions of patients achieving A1C <7% (P = 0.254)", number of patients with A1C <7% , glargine , detemir ,0,
lidija,2366143,No significant difference,". No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", neonatal outcomes , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,2944158,No significant difference,"IV therapy duration did not differ between groups (P = 0.22),", therapy duration , staff inclination replacement , routine replacement ,0,
lidija,2674549,Significantly increased,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively", HAQ-DI score , placebo and methotrexate , 50mg of Golimumab and methotrexate ,0,
lidija,524504,Significantly decreased,"there was less need for oxytocin augmentation (65.8% vs. 81.5%, p < 0.05)", administration of oxytocin augmentation , dinoprostone , misoprostol ,0,
lidija,2674549,Significantly increased,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", HAQ-DI score , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,524504,Significantly decreased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
lidija,3281242,Cannot tell based on the abstract,, time to make first quit attempt , placebo , varenicline ,0,
lidija,3281242,Significantly increased,Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects,  time to make first quit attempt  ,  placebo  ,  varenicline  ,0,
lidija,524504,Significantly increased,"higher abnormal fetal heart rate (FHR) tracings (22.5% vs. 12%, p > 0.05)", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
lidija,524504,Cannot tell based on the abstract,, Hyperbilirubinemia , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,"Hyperbilirubinemia 2	9 (11.3%)	5 (6.0%)	NS",  Hyperbilirubinemia  ,  misoprostol  ,  dinoprostone  ,0,
lidija,1764008,Cannot tell based on the abstract,, nausea and vomiting , epidural analgesia , Meperidine analgesia ,0,
lidija,1764008,No significant difference,There was no significant difference in the incidence of nausea and vomiting between the two groups (epidural 6% vs. meperidine 4%).,  nausea and vomiting  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,2674549,Significantly increased,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group, 55.1% (p = 0.001) in the golimumab 50 mg plus methotrexate group and 56.2% (p<0.001) in the golimumab 100 mg plus methotrexate group.", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,1764008,No significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate., rates of vacuum-assisted delivery rate , epidural analgesia , Meperidine analgesia ,0,
lidija,2944158,Cannot tell based on the abstract,, IVD dwell times , routine replacement , staff inclination replacement ,0,
lidija,2944158,Significantly increased,"For individual IVD dwell times, the clinically indicated group devices had a median dwell time of 85 hours (quartiles 51 and 121 hours), and those replaced routinely had a median dwell time of 71 hours (quartiles 48 and 90 hours) (P < 0.001).",  IVD dwell times  ,  routine replacement  ,  staff inclination replacement  ,0,
lidija,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA and improved physical function., physical function , methotrexate , golimumab and methotrexate ,0,
lidija,524504,Cannot tell based on the abstract,, Uterine Hyperstimulation , dinoprostone , misoprostol ,0,
lidija,524504,Significantly increased,but with increased rates of uterine hyperstimulation both with and without associated fetal heart rate,  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
lidija,3298351,Cannot tell based on the abstract,, venous ulcer healing , no treatment , compression therapy ,0,
lidija,3298351,Invalid Prompt,,  venous ulcer healing  ,  no treatment  ,  compression therapy  ,1," there is not a no treatment group
"
lidija,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", gestational age , placebo , antibiotic therapy ,0,
lidija,3233526,Invalid Prompt,, side effects , no treatment , daily single iron tablets ,1, there is no data for a no treatment group
lidija,3233526,Invalid Prompt,, hemoglobin levels at week 28 , no treatment , twice weekly single iron tablet ,1," there is no ""no treatment"" group"
lidija,2674549,No significant difference,"serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients and serious infections occurred in 0.8%, 0.8%, 2.2% and 5.6%, respectively.", serious adverse events , 50mg of Golimumab and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,2944158,Cannot tell based on the abstract,, infiltration , staff inclination replacement , routine replacement ,0,
lidija,2944158,No significant difference,"5% difference in combined phlebitis and infiltration rates per patient (38% clinically indicated resite, 33% routine resite),",  infiltration  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,2875419,No significant difference,Hypoglycemia risk was similar., Hypoglycemia , glargine , detemir ,0,
lidija,3233526,Significantly increased,There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks., ferritin levels at week 28 , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,3233526,Cannot tell based on the abstract,, side effects , no treatment , twice weekly single iron tablet ,0,
lidija,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  twice weekly single iron tablet  ,0,
lidija,2944158,Significantly increased,with significantly higher hospital costs per patient (P < 0.001)., cost per patient , staff inclination replacement , routine replacement ,0,
lidija,2366143,Cannot tell based on the abstract,, white blood cell count , placebo , antibiotic therapy ,0,
lidija,2366143,Invalid Prompt,,  white blood cell count  ,  placebo  ,  antibiotic therapy  ,1, there is no data on white blood cells count
lidija,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., birth outcome , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,2366143,Cannot tell based on the abstract,, frequency of contractions , placebo , antibiotic therapy ,0,
lidija,2366143,Invalid Prompt,,  frequency of contractions  ,  placebo  ,  antibiotic therapy  ,1, there is no data on frequency of contractions
lidija,524504,Cannot tell based on the abstract,, Meconium stained AF , misoprostol , dinoprostone ,0,
lidija,524504,Significantly decreased,meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group,  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
lidija,524504,Cannot tell based on the abstract,, uterine tachysystole , dinoprostone , misoprostol ,0,
lidija,524504,Significantly increased,uterine tachysystole (p < 0.05)) and meconium stained amniotic fluid (p > 0.05) occurred more often in the misoprostol group,  uterine tachysystole  ,  dinoprostone  ,  misoprostol  ,0,
lidija,1764008,Cannot tell based on the abstract,, pain levels during first stage labor , Meperidine analgesia , epidural analgesia ,0,
lidija,1764008,Significantly decreased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during first stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 μg/L)", ferritin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,2944158,No significant difference,"IVD complication rates were 68 per 1,000 IVD days (clinically indicated) and 66 per 1,000 IVD days (routine replacement) (P = 0.86; HR 1.03; 95% CI, 0.74-1.43).", IVD comlication rates , staff inclination replacement , routine replacement ,0,
lidija,3281242,Cannot tell based on the abstract,, frequency of quit events by day 35 , placebo , varenicline ,0,
lidija,3281242,Significantly increased,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
lidija,2674549,Significantly increased,"HAQ-DI scores were 0.13, 0.13 (p = 0.240), 0.38 (p<0.001) and 0.50 (p<0.001), respectively.", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,2944158,Cannot tell based on the abstract,, frequency of replacements , staff inclination replacement , routine replacement ,0,
lidija,2944158,Significantly increased,A total of 22% of patients in the routinely replaced group had three or more IVDs compared with 9% in the clinical indication group.,  frequency of replacements  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,524504,Significantly increased,"With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05),", number of women who deliver within 24 hours , dinoprostone , misoprostol ,0,
lidija,524504,Cannot tell based on the abstract,, Neonatal resuscitation , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,"Neonatal resuscitation	9 (11.3%)	9 (10.8%)",  Neonatal resuscitation  ,  misoprostol  ,  dinoprostone  ,0,
lidija,2858204,Significantly increased,complete healing of the index ulcer was achieved in 37 patients at 1-year of follow-up: 25/48 (52%) in the HBOT group and 12/42 (29%) in the placebo group, frequency of healed index ucler after 1 year , placebo , HBOT  ,0,
lidija,2875419,Significantly increased,more detemir-treated patients reaching A1C <6.5% (P = 0.017)., number of patients with A1C <6.5% , glargine , detemir ,0,
lidija,2944158,Cannot tell based on the abstract,, IVD complications per person , staff inclination replacement , routine replacement ,0,
lidija,2944158,No significant difference,"There remained no effect when events were expressed per patient or per 1,000 IVD days.",  IVD complications per person  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,2674549,Significantly increased,"serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0%", serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups, birth outcome , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
lidija,2944158,Cannot tell based on the abstract,, phlebitis , staff inclination replacement , routine replacement ,0,
lidija,2944158,No significant difference,"Phlebitis, n (%)	12 (7%)	18 (10%)",  phlebitis  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,1764008,Cannot tell based on the abstract,, oxytocin augmentation , epidural analgesia , Meperidine analgesia ,0,
lidija,1764008,No significant difference,"Oxytocin augmentation After initiation of Analgesia	197(100)	192(96)	NS",  oxytocin augmentation  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,3298351,Cannot tell based on the abstract,, venous ulcer healing , two-layer bandage , four-layer bandage ,0,
lidija,3298351,No significant difference,complete healing was achieved in 10 (62.5%) ulcerations treated with the two-layer compression system and 9 (60%) ulcerations treated with the four-layer compression system.,  venous ulcer healing  ,  two-layer bandage  ,  four-layer bandage  ,0,
lidija,3281242,Significantly increased,Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9–12: 53.1% vs. 19.3%;, continuous abstienence at week 12 , placebo , varenicline ,0,
lidija,2858204,Cannot tell based on the abstract,, hypoglycemia occuring after treatment , placebo , HBOT  ,0,
lidija,2858204,No significant difference,"Hypoglycemia (symptoms and blood-glucose <3.0 mmol/l) within 6 h after treatment occurred in two and four patients in the HBOT and placebo groups, respectively",  hypoglycemia occuring after treatment  ,  placebo  ,  HBOT   ,0,
lidija,2944158,No significant difference,"Time to first complication per patient did not differ between groups (KM with log rank, P = 0.53).", time until first complication , staff inclination replacement , routine replacement ,0,
lidija,1764008,No significant difference,"here was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups. Differences in the duration of the active-first and the second stages of labor were not statistically significant. The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups", obstetric outcome , epidural analgesia , Meperidine analgesia ,0,
lidija,3233526,No significant difference,"Twice-weekly supplementation is as effective as daily supplementation, and may represent an acceptable compromise in iron supplementation regimens for nonanemic pregnant women.", pregnancy , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,2875419,Cannot tell based on the abstract,, frequency of insulin doses , detemir , glargine ,0,
lidija,2875419,Significantly decreased,"nsulin doses, however, were significantly lower for glargine: 43.5 ± 29.0 versus 76.5 ± 50.5 units/day",  frequency of insulin doses  ,  detemir  ,  glargine  ,0,
lidija,3298351,Significantly increased,The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system – on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings – on average 0.44 cm2/per week., venous ulcer healing , compression stocking , four-layer bandage ,0,
lidija,1764008,Cannot tell based on the abstract,, preanalgesic visual analog pain , epidural analgesia , Meperidine analgesia ,0,
lidija,1764008,No significant difference,"The preanalgesic visual analog pain scale scores were similar between the two study groups (epidural, 9 ± 1.2 vs. intravenous meperidine, 9 ± 1.3; P = 0.09).",  preanalgesic visual analog pain  ,  epidural analgesia  ,  Meperidine analgesia  ,0,
lidija,3233526,Invalid Prompt,, hemoglobin levels at week 28 , no treatment , daily single iron tablets ,1," there isn't no treatment group
"
lidija,2674549,Significantly increased,"serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0%", serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
lidija,1764008,No significant difference,"The number of newborns with 1-min and 5-min Apgar scores less than 7, did not differ significantly between both analgesia groups.", neonatal outcome , epidural analgesia , Meperidine analgesia ,0,
lidija,3298351,No significant difference,"the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", higher percentage of healed area , Compression stocking , layer compression ,0,
lidija,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
lidija,3298351,Cannot tell based on the abstract,, faster healing dynamics , Compression stocking , layer compression ,0,
lidija,3298351,Significantly increased,greater dynamics of healing was observed in patients treated with the four-layer Profore system – the average loss of area during the whole 12-week observation period was 0.63 cm2/per week.,  faster healing dynamics  ,  Compression stocking  ,  layer compression  ,0,
lidija,1764008,No significant difference,"There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, as a consequence of fetal bradycardia or dystocia, did not differ significantly between the groups.", c-section , epidural analgesia , Meperidine analgesia ,0,
lidija,2674549,Significantly increased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA, symptoms of RA , methotrexate , golimumab and methotrexate ,0,
lidija,2875419,Cannot tell based on the abstract,, drop-out rate , glargine , detemir ,0,
lidija,2875419,Invalid Prompt,,  drop-out rate  ,  glargine  ,  detemir  ,1, there is no data about drop out rate
lidija,2944158,Cannot tell based on the abstract,, occlusion , staff inclination replacement , routine replacement ,0,
lidija,2944158,No significant difference,"Occlusion, n (%)	5 (3%)	4 (2%)",  occlusion  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,2944158,Cannot tell based on the abstract,, infections , staff inclination replacement , routine replacement ,0,
lidija,2944158,No significant difference,No cases of local infection or IVD-related bloodstream infection occurred in either group.,  infections  ,  staff inclination replacement  ,  routine replacement  ,0,
lidija,3298351,Cannot tell based on the abstract,, CEAP scores , compression stocking , two-layer bandage ,0,
lidija,3298351,No significant difference,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4",  CEAP scores  ,  compression stocking  ,  two-layer bandage  ,0,
lidija,3298351,Cannot tell based on the abstract,, CEAP scores , two-layer bandage , four-layer bandage ,0,
lidija,3298351,Significantly increased,"Initial CEAP score (x ± SD)	11.9 ±1.12	11.2 ±1.3	12.6 ±1.4",  CEAP scores  ,  two-layer bandage  ,  four-layer bandage  ,0,
lidija,3233526,Significantly increased,. There was a significant increase in ferritin in Group C (P = 0.03) at 28 weeks, ferritin levels at week 28 , weekly supplements of two iron tablets , daily single iron tablets ,0,
lidija,3233526,Invalid Prompt,, hemoglobin levels at week 28 , no treatment , weekly supplements of two iron tablets ,1, there are no data for no treatment group
lidija,3233526,Cannot tell based on the abstract,, pregnancy , weekly supplements of two iron tablets , twice weekly single iron tablet ,0,
lidija,3233526,No significant difference,the twice-weekly regime has shown equal effectiveness as a daily supplementation regimen with respect to maintaining safe hemoglobin and ferritin levels throughout pregnancy.,  pregnancy  ,  weekly supplements of two iron tablets  ,  twice weekly single iron tablet  ,0,
lidija,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", birth weight , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,3233526,Cannot tell based on the abstract,, birth outcome , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,3233526,No significant difference,"An overall comparison of average birth parameters for the three treatment groups is summarized in Table 3. Infants born to women who were assigned to the different treatment groups showed no significant difference in average birth weight (P = 0.521). The difference in pregnancy termination week was insignificant across the randomization groups (P = 0.13), as was the incidence of cesarean section births, preterm delivery, and low birth weight across the groups (P = 0.31, 0.25, and 0.33, respectively). Two babies (one in Group A and one in Group C) were of low birth weight, and eight babies (Group A, n = 4; Group B, n = 3; Group C, n = 1) were delivered preterm.",  birth outcome  ,  twice weekly single iron tablet  ,  daily single iron tablets  ,0,
lidija,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant", ferritin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
lidija,2366143,Cannot tell based on the abstract,, interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,2366143,Invalid Prompt,,  interval to delivery  ,  antibiotic therapy and tocolysis  ,  tocolysis  ,1, there is no data
lidija,1764008,No significant difference,There was no statistical difference in rates of vacuum-assisted delivery rate. Cesarean deliveries, obstetric intervention , epidural analgesia , Meperidine analgesia ,0,
lidija,3233526,No significant difference,"There was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant", ferritin levels at week 38 , daily single iron tablets , weekly supplements of two iron tablets ,0,
lidija,524504,Cannot tell based on the abstract,, Core blood pH , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,"Cord blood pH (arterial)1	7.28 ± 0.05	7.27 ± 0.05	NS",  Core blood pH  ,  misoprostol  ,  dinoprostone  ,0,
lidija,524504,Cannot tell based on the abstract,, perinatal death , misoprostol , dinoprostone ,0,
lidija,524504,Cannot tell based on the abstract,, Birth trauma , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,"Birth trauma 3	0	2 (2.5%)	NS",  Birth trauma  ,  misoprostol  ,  dinoprostone  ,0,
lidija,2858204,Cannot tell based on the abstract,, downsizing of ucler area 2 weeks after treatment , placebo , HBOT  ,0,
lidija,2858204,Significantly increased,"After two weeks of treatment, the reduction in ulcer area was doubled in the HBOT group (P = 0.037).",  downsizing of ucler area 2 weeks after treatment  ,  placebo  ,  HBOT   ,0,
lidija,3233526,Cannot tell based on the abstract,, hemoglobin levels at week 38 , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,3233526,No significant difference,"At 38 weeks, the mean hemoglobin level in Group B was significantly lower than in Group A and Group C (P = 0.018), but the difference was of no clinical significance.",  hemoglobin levels at week 38  ,  twice weekly single iron tablet  ,  daily single iron tablets  ,0,
lidija,1764008,Cannot tell based on the abstract,, hypotension , Meperidine analgesia , epidural analgesia ,0,
lidija,1764008,Significantly increased,Women who received epidural analgesia had a significantly higher incidence of hypotension compared with women who received intravenous meperidine (30% vs. 0; P < 0.0001),  hypotension  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,2366143,Significantly decreased,Women in the antibiotic group had a significantly lower incidence of postpartum infections compared with women in the placebo group., infection , placebo , antibiotic therapy ,0,
lidija,3233526,No significant difference,No significant difference was observed with respect to pregnancy or birth outcome across the groups., pregnancy , twice weekly single iron tablet , daily single iron tablets ,0,
lidija,3298351,No significant difference,"However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , Profore compression , ProGuide system ,0,
lidija,524504,No significant difference,"Although not statistically significant, a lower Caesarean section (CS) rate was observed with misoprostol", Caesarean section rate , misoprostol , dinoprostone ,0,
lidija,2875419,No significant difference,Improvements in A1C were −1.46 ± 1.09% for glargine and −1.54 ± 1.11% for detemir (P = 0.149), improved A1C , glargine , detemir ,0,
lidija,524504,Significantly increased,". With misoprostol, more women delivered within 12 hours (57.5% vs. 32.5%, p < 0.01) and 24 hours (98.7% vs. 91.4%, p < 0.05), spontaneous rupture of the membranes occurred more frequently (38.8% vs. 20.5%, p < 0.05)", spontaneous rupture of membranes , dinoprostone , misoprostol ,0,
lidija,1764008,Cannot tell based on the abstract,, pain levels during second stage labor , Meperidine analgesia , epidural analgesia ,0,
lidija,1764008,Significantly increased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,3298351,Cannot tell based on the abstract,, CEAP scores , compression stocking , four-layer bandage ,0,
lidija,3298351,No significant difference,"11.9 ±1.12	11.2 ±1.3	12.6 ±1.4	p > 0.05",  CEAP scores  ,  compression stocking  ,  four-layer bandage  ,0,
lidija,3233526,Cannot tell based on the abstract,, side effects , no treatment , weekly supplements of two iron tablets ,0,
lidija,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,524504,Significantly decreased,"The induction-delivery interval was significantly lower in the misoprostol group than in the dinoprostone group (11.9 h vs. 15.5 h, p < 0.001).", induction-delivery interval , dinoprostone , misoprostol ,0,
lidija,2875419,Significantly increased,"Weight gain was higher for glargine (difference: 0.77 kg, P < 0.001).", Weight Gain , detemir , glargine ,0,
lidija,524504,Significantly increased,"<td colspan=""6""><hr></td>", number of women who deliver within 12 hours , dinoprostone , misoprostol ,0,
lidija,3281242,Cannot tell based on the abstract,, time to make first quit attempt , placebo , varenicline ,0,
lidija,3281242,Significantly increased,Varenicline-treated subjects made their first quit attempt significantly earlier than placebo-treated subjects (p = .0074),  time to make first quit attempt  ,  placebo  ,  varenicline  ,0,
lidija,524504,No significant difference,"<td colspan=""6""><hr></td>", abnormal fetal heart rate , misoprostol , dinoprostone ,0,
lidija,2674549,No significant difference,"The proportion of patients who achieved an ACR20 response at week 14 was 33.1% in the placebo plus methotrexate group, 44.4% (p = 0.059) in the golimumab 100 mg plus placebo group,", ACR20  , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,524504,Cannot tell based on the abstract,, Uterine Hyperstimulation , dinoprostone , misoprostol ,0,
lidija,524504,No significant difference,"<td colspan=""6""><hr></td>",  Uterine Hyperstimulation  ,  dinoprostone  ,  misoprostol  ,0,
lidija,3298351,Cannot tell based on the abstract,, venous ulcer healing , no treatment , compression therapy ,0,
lidija,3298351,Invalid Prompt,,  venous ulcer healing  ,  no treatment  ,  compression therapy  ,1," there is no  ""no treatment"" group"
lidija,3233526,Cannot tell based on the abstract,, side effects , no treatment , daily single iron tablets ,0,
lidija,3233526,No significant difference,No side effects were reported throughout the duration of the study.,  side effects  ,  no treatment  ,  daily single iron tablets  ,0,
lidija,3233526,Cannot tell based on the abstract,, hemoglobin levels at week 28 , no treatment , twice weekly single iron tablet ,0,
lidija,3233526,Invalid Prompt,,  hemoglobin levels at week 28  ,  no treatment  ,  twice weekly single iron tablet  ,1," there is no ""no treatment"" group"
lidija,524504,Cannot tell based on the abstract,, Meconium stained AF , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,"<td colspan=""6""><hr></td>",  Meconium stained AF  ,  misoprostol  ,  dinoprostone  ,0,
lidija,3281242,Cannot tell based on the abstract,, frequency of quit events by day 35 , placebo , varenicline ,0,
lidija,3281242,No significant difference,"By the end of the quit window (Day 35), 391 (80.5%) varenicline subjects and 121 (73.3%) placebo subjects reported making a quit attempt (p = .062).",  frequency of quit events by day 35  ,  placebo  ,  varenicline  ,0,
lidija,2674549,No significant difference,"At week 24, median improvements from baseline in HAQ-DI scores were 0.13, 0.13 (p = 0.240),", Median HAQ-DI score , Golimumab 100 mg and placebo , placebo and methotrexate ,0,
lidija,2674549,Cannot tell based on the abstract,, serious adverse events , placebo and methotrexate , 100mg of Golimumab and methotrexate ,0,
lidija,2674549,Significantly increased,"Serious adverse events occurred in 2.3%, 3.8%, 5.6% and 9.0% of patients, respectively.,The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;,<td align=""left"" colspan=""1"" rowspan=""1"">Serious adverse events</td><td align=""char"" colspan=""1"" rowspan=""1"">5 (3.7%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.09 (0.03 to 0.21)</td><td align=""char"" colspan=""1"" rowspan=""1"">8 (6.0%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.11 (0.06 to 0.19)</td><td align=""char"" colspan=""1"" rowspan=""1"">9 (4.2%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.08 (0.04 to 0.14)</td><td align=""char"" colspan=""1"" rowspan=""1"">13 (12.4%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.18 (0.10 to 0.30)</td>",  serious adverse events  ,  placebo and methotrexate  ,  100mg of Golimumab and methotrexate  ,0,
lidija,3298351,No significant difference,"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system – on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings – on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", venous ulcer healing , compression stocking , four-layer bandage ,0,
lidija,3233526,Invalid Prompt,, hemoglobin levels at week 28 , no treatment , daily single iron tablets ,1," there is no ""no treatment"" group"
lidija,2674549,Cannot tell based on the abstract,, serious adverse events , Golimumab 100 mg and placebo , 100mg of Golimumab and methotrexate ,0,
lidija,2674549,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"">Serious adverse events</td><td align=""char"" colspan=""1"" rowspan=""1"">5 (3.7%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.09 (0.03 to 0.21)</td><td align=""char"" colspan=""1"" rowspan=""1"">8 (6.0%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.11 (0.06 to 0.19)</td><td align=""char"" colspan=""1"" rowspan=""1"">9 (4.2%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.08 (0.04 to 0.14)</td><td align=""char"" colspan=""1"" rowspan=""1"">13 (12.4%)</td><td align=""char"" colspan=""1"" rowspan=""1"">0.18 (0.10 to 0.30)</td>,The numbers of serious adverse events and serious infections per patient-year were greater in group 4 than in groups 1, 2 or 3;",  serious adverse events  ,  Golimumab 100 mg and placebo  ,  100mg of Golimumab and methotrexate  ,0,
lidija,3298351,No significant difference,"The largest loss of ulceration area in each of the successive measurements was observed in patients treated with the four-layer system – on average 0.63 cm2/per week. The smallest loss of ulceration area was observed in patients using compression stockings – on average 0.44 cm2/per week. However, the observed differences were not statistically significant (Kruskal-Wallis test H = 4.45, p > 0.05).", higher percentage of healed area , Compression stocking , layer compression ,0,
lidija,3233526,No significant difference,"here was a significant difference in mean hemoglobin and ferritin levels in Group B at 38 weeks (P = 0.018 and P = 0.035, respectively) but this difference was not clinically significant (hemoglobin >12 g/dL, ferritin >19 μg/L).", hemoglobin levels at week 38 , twice weekly single iron tablet , weekly supplements of two iron tablets ,0,
lidija,2674549,Significantly decreased,The addition of golimumab to methotrexate in patients with active RA despite methotrexate therapy significantly reduced the signs and symptoms of RA, symptoms of RA , methotrexate , golimumab and methotrexate ,0,
lidija,2875419,Cannot tell based on the abstract,, drop-out rate , glargine , detemir ,0,
lidija,2875419,Significantly increased,"our study confirms the higher weight gain, lower daily insulin doses, and fewer drop-outs (because of adverse events) for glargine versus detemir,",  drop-out rate  ,  glargine  ,  detemir  ,0,
lidija,3233526,Cannot tell based on the abstract,, hemoglobin levels at week 28 , no treatment , weekly supplements of two iron tablets ,0,
lidija,3233526,No significant difference,No significant difference was found between the treatment groups for hemoglobin levels at 28 weeks.,  hemoglobin levels at week 28  ,  no treatment  ,  weekly supplements of two iron tablets  ,0,
lidija,2366143,No significant difference,"No significant differences in the interval to delivery, birth weight, and neonatal outcomes were observed between the 2 groups.", interval to delivery , antibiotic therapy and tocolysis , tocolysis ,0,
lidija,524504,Cannot tell based on the abstract,, perinatal death , misoprostol , dinoprostone ,0,
lidija,524504,No significant difference,Perinatal death 0 1(1.2%) NS ,  perinatal death  ,  misoprostol  ,  dinoprostone  ,0,
lidija,1764008,Cannot tell based on the abstract,, pain levels during second stage labor , Meperidine analgesia , epidural analgesia ,0,
lidija,1764008,Significantly increased,"Women who received epidural analgesia reported lower pain scores during the first stage (epidural, 3 ± 3 vs. meperidine, 6 ± 4; P < 0.0001) and second stage (epidural, 4 ± 3 vs. meperidine, 8 ± 2; P < 0.0001) of labor.",  pain levels during second stage labor  ,  Meperidine analgesia  ,  epidural analgesia  ,0,
lidija,2517154,No significant difference,Pain severity decreased during the treatment by 30% in both the placebo (P < 0.001) and infliximab groups (P < 0.001)., Dysmenorrhea scores , Placebo , Infliximab ,0,
lidija,2708184,Cannot tell based on the abstract,, 6-minute walk test , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,Cannot tell based on the abstract,, 6-minute walk test , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,No significant difference,"<td colspan=""8""><hr></td>",  6-minute walk test  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,2871176,Significantly increased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,No significant difference,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride", Patients reaching HbA1c goals less than 7.0%  , Liraglutide (1.2 mg) plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups", C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2864284,Cannot tell based on the abstract,, Pruritus , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>,  Pruritus  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1"">Liraglutide 1.2 mg</td><td align=""center"" colspan=""1"" rowspan=""1"">0.45 ± 0.31</td><td align=""center"" colspan=""1"" rowspan=""1"">0.33 ± 0.20</td><td align=""center"" colspan=""1"" rowspan=""1"">−0.10 (−0.16; −0.05)<xref ref-type=""table-fn"" rid=""tf2-2"">†</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">−0.07 (−0.11; −0.02)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td>,P < 0.0001.",  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1""></td><td align=""left"" colspan=""1"" rowspan=""1"">Liraglutide 1.8 mg</td><td align=""center"" colspan=""1"" rowspan=""1"">0.48 ± 0.33</td><td align=""center"" colspan=""1"" rowspan=""1"">0.36 ± 0.20</td><td align=""center"" colspan=""1"" rowspan=""1"">−0.09 (−0.15; −0.03)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td><td align=""center"" colspan=""1"" rowspan=""1"">−0.05 (−0.10; −0.01)<xref ref-type=""table-fn"" rid=""tf2-1"">*</xref></td>,P≤ 0.05;",  Proinsulin : insulin ratio  ,  Placebo plus glimepiride   ,  Liraglutide (1.8 mg) plus glimepiride   ,0,
lidija,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).",  Reductions in systolic blood pressure  ,  Rosiglitazone plus glimepiride   ,  Liraglutide (1.2 mg) plus glimepiride   ,0,
lidija,2517154,Cannot tell based on the abstract,, Tissue examination by routine pathology , Placebo , Infliximab ,0,
lidija,2517154,Invalid Prompt,,  Tissue examination by routine pathology  ,  Placebo  ,  Infliximab  ,1, there is no data on pathology examination
lidija,2708184,Cannot tell based on the abstract,, Berg Balance Scale score , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Body-weight supported treadmill training combined with Lokomat (Pre-test)  ,  Body-weight supported treadmill training combined with Lokomat (Post-test)  ,0,
lidija,2517154,No significant difference,"After surgery, pain scores decreased in both groups to less than 20% of the initial value.", Pain estimates after surgery , Placebo , Infliximab ,0,
lidija,2864284,Cannot tell based on the abstract,, Headache , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly increased,<td></td><td></td><td></td><td></td>,  Headache  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,2864284,Cannot tell based on the abstract,, Parasitaemias associated with gametocytaemia , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,No significant difference,<td></td><td></td><td></td><td></td>,  Parasitaemias associated with gametocytaemia  ,  Chloroquine  ,  Dihydroartemisinin-piperaquine  ,0,
lidija,2871176,Invalid Prompt,, Pulse variations , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,1,Server bug
lidija,2871176,No significant difference,"<td align=""left""> Group A</td><td align=""left"">60 ± 12</td><td align=""left"">76 ± 14</td><td align=""left"">78 ± 13</td><td align=""left"">84 ± 18</td><td align=""left"">84 ± 7</td><td align=""left"">92 ± 10</td><td></td>",  Pulse variations  ,  Placebo plus glimepiride  ,  Liraglutide (all doses) plus glimepiride  ,0,
lidija,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,Cannot tell based on the abstract,, Pain relief: Acupuncture , Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).",  Pain relief: Acupuncture  , Normal unit & Special unit ,  Midwife-led unit  ,0,
lidija,1852268,No significant difference,"At the primary efficacy endpoint 2–4 weeks post therapy, 93.9% of patients who received ertapenem and 91.5% of those who received piperacillin–tazobactam were cured (95% confidence interval for the difference, adjusting for strata, –4% to 8.8%), indicating that cure rates for both treatment groups were equivalent. Cure rates for both treatment groups were also similar when compared by stratum and severity of infection", obstetric/postpartum infection or gynecologic/postoperative infection ," Intravenous piperacillin–tazobactam, 3.375 g every 6 hours "," Inravenous ertapenem, 1 g once a day ",0,
lidija,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , high Ab group ,0,
lidija,4106715,Significantly increased,"Subjects with high Ab were also significantly more likely to be abstinent for 12 months compared to placebo (18.0% vs. 6.0%, p=0.014; OR of 3.84; 95% CI, 1.32–11.20).",  Prolonged abstinence from smoking rates to 12 months  ,  placebo  ,  high Ab group  ,0,
lidija,2708184,Cannot tell based on the abstract,, Berg Balance Scale score , Manually-assisted body-weight supported treadmill training (pre-test) , Manually-assisted body-weight supported treadmill training (post-test) ,0,
lidija,2708184,Significantly decreased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>",  Berg Balance Scale score  ,  Manually-assisted body-weight supported treadmill training (pre-test)  ,  Manually-assisted body-weight supported treadmill training (post-test)  ,0,
lidija,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Cannot tell based on the abstract,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Invalid Prompt,, C-reactive protein (mg/l) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,1,Server bug
lidija,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2708184,Cannot tell based on the abstract,, Late Life Function and Disability Instrument , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,No significant difference,"<td colspan=""8""><hr></td>", Late Life Function and Disability Instrument , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups."," The durations of mechanical ventilation, ICU stay and use of paralysing or sedative agents of patients with ARDS ", table-based PEEP (control) group , Decremental PEEP titration group ,0,
lidija,2871176,Significantly increased,"Changes in body weight with liraglutide 1.8 mg (−0.2 kg, baseline 83.0 kg), 1.2 mg (+0.3 kg, baseline 80.0 kg) or placebo (−0.1 kg, baseline 81.9 kg) were less than with rosiglitazone (+2.1 kg, P < 0.0001, baseline 80.6 kg)", Weight gain , Liraglutide plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2206488,Significantly decreased,"In group A, lower peak (median) plasma levels of procalcitonin (0.2 versus 1.4, p < 0.001), IL 8 (5.6 versus 94.8, p < 0.001), IL 10 (47.2 versus 209.7, p = 0.001), endothelial leukocyte adhesion molecule-1 (88.5 versus 130.6, p = 0.033), intercellular adhesion molecule-1 (806.7 versus 1,375.7, P = 0.001) and troponin-I (0.22 versus 0.66, p = 0.018) were found."," Procalcitonin, IL 8, IL 10, endothelial leukocyte adhesion molecule-1, intercellular adhesion molecule-1, troponin-I ", identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2864284,Cannot tell based on the abstract,, Parasite clearance at day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Parasite clearance at day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01)", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2206488,Cannot tell based on the abstract,, Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Significantly increased,"<td align=""left""> Group A</td><td align=""left"">2.3 ± 0.45</td><td align=""left"">2.4 ± 0.39</td><td align=""left"">2.4 ± 0.63</td><td align=""left"">2.7 ± 0.63</td><td align=""left"">3.0 ± 0.98</td><td align=""left"">3.4 ± 0.94</td><td></td>", Cardiac index  , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%)., ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"After 26 weeks, HbA1c decreased by 1.1% from baseline (primary endpoint) with either liraglutide 1.2 or 1.8 mg, respectively, compared with either placebo (+0.2%) or rosiglitazone (−0.4%)", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,4106715,No significant difference,"The low Ab group did not differ significantly from placebo (7.1% vs. 6.0%, p=0.67).", Prolonged abstinence from smoking rates to 12 months , placebo , low Ab group ,0,
lidija,2708184,Significantly decreased,"<td colspan=""8""><hr></td>", Paretic step length ratio , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage,", Postpartum haemorrhage , Normal unit & Special unit , Midwife-led unit ,0,
lidija,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups.", IL-6 (pg/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Cure rate at day 28 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2708184,Significantly increased,"<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Manually-assisted body-weight supported treadmill training , Body-weight supported treadmill training combined with Lokomat ,0,
lidija,2517154,Cannot tell based on the abstract,, Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis", Extend of the disease as visualized during surgery , Placebo , Infliximab ,0,
lidija,2871176,Significantly decreased,"Fasting plasma glucose decreased by week 2, with a 1.6 mmol/l decrease from baseline at week 26 with liraglutide 1.2 mg (baseline 9.8 mmol/l) or 1.8 mg (baseline 9.7 mmol/l) compared with a 0.9 mmol/l increase (placebo, P < 0.0001, baseline 9.5 mmol/l) or 1.0 mmol/l decrease (rosiglitazone, P < 0.006, baseline 9.9 mmol/l).", Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001), ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,3001156,Cannot tell based on the abstract,, Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,3001156,Significantly increased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">  Chi-square trend test for care from Kumudini Hospital, comparison Group</td><td align=""left"" colspan=""6"" rowspan=""1"" valign=""top"">Chi-square for linear trend=4.47, df=1, p=0.035</td>", Care-seeking from the Kumudini Hospital for ill newborns  , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l)", Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,3187863,Cannot tell based on the abstract,," Neonatal outcomes were evaluated by Apgar score &lt;7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,No significant difference,"An Apgar score <7 at 5 minutes was observed in 1.0, 1.4 and 0.4% of cases in the MU, NU and SU, respectively. An umbilical cord pH test was taken in 57.7, 68.8 and 77.3% of the cases in the MU, NU and SU, respectively. Metabolic acidosis was stated in 2.2, 2.8 and 2.0% in the MU, NU and SU, respectively. Transfers to the NICU were conducted in 7.8, 6.2 and 6.7% of the cases in the MU, NU and SU, respectively (Table 3). None of these outcomes showed a statistically significant difference between the units (Table 2)."," Neonatal outcomes were evaluated by Apgar score &lt;7 at 5 minutes, metabolic acidosis and transfer to NICU within 2 hours of birth ", Normal unit & Special unit , Midwife-led unit ,0,
lidija,4106715,Significantly increased,"3’AmNic-rEPA recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) were significantly more likely to attain 8 weeks continuous abstinence from weeks 19 through 26 than the placebo recipients (24.6% vs. 12.0%, p=0.024, OR=2.69, 95% CI, 1.14–6.37).", attain 8 weeks continuous abstinence from weeks 19 through 26 , placebo group , recipients with the highest serum anti-nicotine antibody response (top 30% by AUC) ,0,
lidija,2871176,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%)", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,4106715,Cannot tell based on the abstract,, Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19–52) with high Ab levels ,0,
lidija,4106715,No significant difference,"The difference in the median reduction in cigarette consumption, following the TQD, between the high Ab non-abstainers and placebo non-abstainers was on average 4.6 cigarettes per day. Similarly, cotinine geometric mean concentrations (GMCs) were 19.0% lower on average following the target quit date in the high Ab non-abstainers as compared to placebo non-abstainers.,No significant compensatory smoking in response to the presence of anti-nicotine antibodies, as determined by the number of cigarettes smoked per day, carbon monoxide levels or cotinine levels, was observed in this study.", Reduction of daily cigarette consumption and cotinine , non-abstainers in the placebo group , non-abstainers (weeks 19–52) with high Ab levels ,0,
lidija,2864284,No significant difference,<td></td><td></td><td></td><td></td>, Serious adverse events , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Significantly decreased,"Liraglutide (1.2 or 1.8 mg) produced greater reductions in HbA1c from baseline, (−1.1%, baseline 8.5%) compared with placebo (+0.2%, P < 0.0001, baseline 8.4%) or rosiglitazone (−0.4%, P < 0.0001, baseline 8.4%) when added to glimepiride.", HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,3187863,Cannot tell based on the abstract,, Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,Significantly decreased,"Of all women allocated to the MU, 26.2% were given oxytocin infusion for augmentation of labour, which was significantly lower than 36.7% in the NU (RR 0.73, 95% CI 0.59–0.89) and 38.0% in the SU (RR 0.69, 95% CI 0.56–0.86)", Oxytocin infusion for augmentation of labour , Normal unit & Special unit , Midwife-led unit ,0,
lidija,2517154,Cannot tell based on the abstract,, Nodules diameters , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,No effect of treatment was found upon the mean diameters of the nodules as measured by TVU., Nodules diameters , Placebo , Infliximab ,0,
lidija,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
lidija,4106715,Significantly increased,"subjects with high Ab levels were significantly more likely to abstain compared to placebo at 26 weeks (36.1% vs. 16.0%, p=0.0024, OR=3.30, 95% CI, 1.53–7.13)", Prolonged abstinence from smoking rates to 6 months , placebo , high Ab group ,0,
lidija,2864284,Cannot tell based on the abstract,, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Parasite clearance at day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2517154,Cannot tell based on the abstract,, Pain killers intake , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"Over the whole observation period, the infliximab group had a slightly higher intake of pain killers (P < 0.01), and higher dysmenorrhea scores (P < 0.001 for physician assessment, for patient VAS scales and for patient diary).", Pain killers intake , Placebo , Infliximab ,0,
lidija,3187863,Cannot tell based on the abstract,, Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,Significantly decreased,"In the MU dystocia was recorded in 29.1% of the cases, which is a significantly lower rate than 36.9% in the NU (RR 0.79, 95% CI 0.65–0.96) and 40.4% in the SU (RR 0.72, 95% CI 0.59–0.89)", Labour dystocia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,2517154,Cannot tell based on the abstract,, Surgery duration , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Surgery duration , Placebo , Infliximab ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,Significantly increased,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05),", HOMA-B , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001),", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2864284,Cannot tell based on the abstract,, Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly increased,"<td align=""left"">Median white blood cells ×10<sup>9</sup>/ml, median (range)</td><td align=""left"">6.0 (3.6-54)</td><td align=""left"">6.6 (3.0-12.4)</td><td align=""left"">0.02</td>", Baseline white blood cell count , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,3001156,Cannot tell based on the abstract,, Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,3001156,Significantly decreased,"<td align=""left"" colspan=""1"" rowspan=""1"" valign=""top"">Chi-square trend test for care from unqualified providers, comparison group</td><td align=""left"" colspan=""6"" rowspan=""1"" valign=""top"">Chi-square for linear trend=0.90, df=1, p=0.34</td>", Care-seeking from unqualified providers (such as village doctors) for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2206488,No significant difference,"There was no significant difference in IL 6, IL-6r and C-reactive protein values between groups", IL-6r (ng/ml) , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003), with more patients reaching < 7.0% with liraglutide 1.8 mg compared with 1.2 mg (P = 0.018).", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg).", Reductions in systolic blood pressure , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,3001156,Significantly increased,". Increases were observed in self-referral of sick newborns for care, compliance after referral by the CHWs, and care-seeking from qualified providers and from the Kumudini Hospital,", Care-seeking from qualified providers for ill newborns   , Comparison arm  , Promotion by CHWs of maternal and newborn-care interventions  ,0,
lidija,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,2871176,Significantly decreased,Rosiglitazone also was superior to placebo (P < 0.0001)., HbA1c level at 26 weeks , Placebo plus glimepiride , Rosiglitazone plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"All liraglutide doses were superior to placebo (P < 0.0001),", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"Pulse increases above baseline ranged from 2 to 4 beats/min with the three doses of liraglutide and 1 beat/min with rosiglitazone, while pulse decreased by 1 beat/min with placebo. Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002)", Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001,", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2864284,Cannot tell based on the abstract,, Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,No significant difference,"<td align=""left"">Haemoglobin concentration, mean g/dl (SD)</td><td align=""left"">10.9 (1.46)</td><td align=""left"">10.9 (1.42)</td><td align=""left"">0.99</td>,<td></td><td></td><td></td><td></td>", Haemoglobin concentration , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"At week 26, 42% and 21% of subjects treated with liraglutide 1.8 mg reached an HbA1c < 7.0% and ≤ 6.5%, respectively, compared with 8% and 4% for placebo", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2517154,Cannot tell based on the abstract,, Bleeding during surgery , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis), the duration of surgery and bleeding estimates.", Bleeding during surgery , Placebo , Infliximab ,0,
lidija,2708184,No significant difference,"<td colspan=""8""><hr></td>", Locomotor-training effects , Slow treadmill speed , Fast treadmill speed ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"The liraglutide 1.2 and 1.8 mg treatment groups also had more subjects achieving the same FPG target at end of treatment compared with rosiglitazone (26%) (P = 0.007 and P = 0.01, respectively).", ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05)", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2708184,Cannot tell based on the abstract,, Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,No significant difference,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Self-selected overground walk velocity , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2871176,Significantly decreased,"Decreases in postprandial plasma glucose from baseline were greater with liraglutide 1.2 or 1.8 mg [−2.5 to −2.7 mmol/l (baseline 12.9 mmol/l for both)] compared with placebo (−0.4 mmol/l, P < 0.0001, baseline 12.7 mmol/l) or rosiglitazone (−1.8 mmol/l, P < 0.05, baseline 13.0 mmol/l).", Postprandial plasma glucose , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2517154,Cannot tell based on the abstract,, Endometrial thickness , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"Endometrial thickness was not affected by treatment, being at baseline and at the end of the treatment period for the infliximab group 5.2 (range 1.3–18) and 7.8 (1.9–11) mm and for the placebo group 7.7 (1.8–23) and 8.2 (3–15) mm, respectively.", Endometrial thickness , Placebo , Infliximab ,0,
lidija,2864284,Cannot tell based on the abstract,, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 2 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02), Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Superiority of treatment given by survival curves , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05)", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2864284,Cannot tell based on the abstract,, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly increased,<td></td><td></td><td></td><td></td>, Fever resolution by day 1 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,The percentage of subjects achieving FPG values between 5.0 mmol/l and ≤ 7.2 mmol/l (ADA target) after 26 weeks was higher with liraglutide: 0.6 mg (19%; P = 0.002); 1.2 mg (37%; P < 0.001); and 1.8 mg (38%;P < 0.001) compared with placebo (7%), ADA fasting plasma glucose goals between 5.0 mmol/l and less than 7.2 mmol/l , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2517154,Cannot tell based on the abstract,, Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
lidija,2517154,No significant difference,"During surgery, no obvious differences were observed in the extend of the disease, the macroscopic aspect of endometriosis (vascularization and sclerosis),", Macroscopic aspect of the tissue , Placebo , Infliximab ,0,
lidija,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo or rosiglitazone (0.9–2.3 mmHg)", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2708184,Cannot tell based on the abstract,, Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,Significantly increased,"<td colspan=""8""><hr></td>", Physical performance battery scores , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2871176,Cannot tell based on the abstract,, ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,"The percentage of subjects with one, two or three PPG measurements < 10.0 mmol/l (ADA target) were greater for all doses of liraglutide compared with placebo (P < 0.05) but not rosiglitazone.", ADA postprandial plasma glucose goals less than 10.0 mmol/l , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Significantly decreased,Reductions in the proinsulin : insulin ratio were greater with both liraglutide 1.2 and 1.8 mg compared with either rosiglitazone or placebo (Table 2; P ≤ 0.02)., Proinsulin : insulin ratio , Rosiglitazone plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,There were no significant differences between treatments for HOMA-IR., HOMA-IR , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,4106715,Cannot tell based on the abstract,, Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
lidija,4106715,No significant difference,"Prolonged abstinence rates to 6 months were significantly higher in the high Ab group vs. placebo (19.7% vs. 6.0%, p=0.0060, OR=4.41, 95% CI, 1.53–12.71) with no significant differences between the placebo and low Ab groups (7.9% vs. 6.0%, p=0.60).", Prolonged abstinence from smoking rates to 6 months , placebo , low Ab group ,0,
lidija,2864284,Cannot tell based on the abstract,, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2864284,Significantly decreased,<td></td><td></td><td></td><td></td>, Recurrent infections at day 56 , Chloroquine , Dihydroartemisinin-piperaquine ,0,
lidija,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,Treatment differences for PPG were greater with all doses of liraglutide compared with placebo (1.5–2.4 mmol/l; P < 0.0001), Postprandial plasma glucose , Placebo plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"The estimated proportion of subjects treated with either liraglutide 1.2 or 1.8 mg reaching ADA/EASD and IDF/AACE HbA1c targets was substantially greater compared with either placebo (P < 0.0001) or rosiglitazone (Fig. 4; P ≤ 0.0003),", Patients reaching HbA1c goals less than 7.0% and equal or less than 6.5% , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,"Reductions in diastolic blood pressure also occurred with all treatments (0.7–1.4 mmHg), with no significant differences between treatments.", Decreases in diastolic blood pressure , Placebo plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2708184,Cannot tell based on the abstract,, Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2708184,Significantly increased,"<td colspan=""8""><hr></td>,<td colspan=""8""><hr></td>", Improvement in lower extremity Fugl-Meyer score  , Body-weight supported treadmill training combined with Lokomat (Pre-test) , Body-weight supported treadmill training combined with Lokomat (Post-test) ,0,
lidija,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,An 0.7-mmol/l greater reduction in FPG was achieved with either liraglutide 1.2 or 1.8 mg compared with rosiglitazone (P ≤ 0.006) after 26 weeks., Fasting plasma glucose at week 26 , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2871176,No significant difference,Liraglutide 0.6 mg was non-inferior to rosiglitazone, HbA1c level at 26 weeks , Rosiglitazone plus glimepiride , Liraglutide (0.6 mg) plus glimepiride ,0,
lidija,2517154,Cannot tell based on the abstract,, Severity of pain , Placebo , Infliximab ,0,
lidija,2517154,Invalid Prompt,, Severity of pain , Placebo , Infliximab ,1, there is no data for pain levels
lidija,2871176,Cannot tell based on the abstract,, Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,No significant difference,"Although decreases in systolic blood pressure occurred with either liraglutide 1.2 or 1.8 mg (2.6–2.8 mmHg), they were not significantly different from placebo", Reductions in systolic blood pressure , Placebo plus glimepiride  , Liraglutide (1.2 mg) plus glimepiride  ,0,
lidija,2871176,Cannot tell based on the abstract,, Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2871176,No significant difference,No significant differences in calcitonin were found between the three groups treated with liraglutide when compared with either placebo or rosiglitazone at the end of the trial at week 26., Changes in calcitonin at week 26 , Rosiglitazone plus glimepiride , Liraglutide (all doses) plus glimepiride ,0,
lidija,2206488,Cannot tell based on the abstract,, systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,2206488,Significantly decreased,"Systemic vascular resistance index (dyn s/cm5 m2)	0.005", systemic vascular resistance , identical amounts of gelatin infusion , dextran-70 infusion was administered at a dose of 7.5 ml/kg before the initiation of cardiopulmonary bypass and at a dose of 12.5 ml/kg after the cessation of cardiopulmonary bypass ,0,
lidija,3187863,Cannot tell based on the abstract,, Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,3187863,Significantly decreased,"Of all women randomised to the MU, 15.8% had an epidural, which is a significantly lower rate than 23.3% in the NU (RR 1.47, 95% CI 1.11–1.96) and 24.8% in the SU (RR 1.57, 95% CI 1.16–2.13).", Pain relief: Epidural anesthesia , Normal unit & Special unit , Midwife-led unit ,0,
lidija,2871176,Cannot tell based on the abstract,, Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"At week 26, all doses of liraglutide decreased FPG more than did placebo (Fig. 5; P < 0.0001)", Fasting plasma glucose at week 26 , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,3187863,No significant difference,"There were no significant differences in postpartum haemorrhage, sphincter injuries or in neonatal outcomes.", Perineal outcome: the number of episiotomies or the incidence of sphincter injuries , Normal unit & Special unit , Special unit ,0,
lidija,2688140,No significant difference,"The duration of use of paralysing or sedative agents, mechanical ventilation, stay in the intensive care unit and mortality at 28 days did not differ significantly between the decremental PEEP titration and control groups.", The survival rate / overall mortality of patients with ARDS , table-based PEEP (control) group , Decremental PEEP titration group ,0,
lidija,2871176,Cannot tell based on the abstract,, HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,No significant difference,"HOMA-B increased with liraglutide (1.8 or 1.2 mg) compared with rosiglitazone (P < 0.05), while this increase was only different to placebo with liraglutide 1.2 mg (P = 0.01) and not liraglutide 1.8 mg (P = 0.051)", HOMA-B , Placebo plus glimepiride  , Liraglutide (1.8 mg) plus glimepiride  ,0,
lidija,2871176,Cannot tell based on the abstract,, Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,Changes in pulse for all doses of liraglutide were significant vs. placebo (P ≤ 0.002). This also was true with either liraglutide 1.8 or 1.2 mg compared with rosiglitazone (P < 0.01)., Pulse variations , Rosiglitazone plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,"Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone and liraglutide 1.2 mg compared with placebo (P = 0.048),", Incidence of minor hypoglycaemia , Placebo plus glimepiride , Liraglutide (1.2 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly increased,Incidence was higher with liraglutide 1.2 mg (P = 0.0024) and 1.8 mg (P = 0.0065) compared with rosiglitazone, Incidence of minor hypoglycaemia , Rosiglitazone plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Cannot tell based on the abstract,, HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
lidija,2871176,Significantly decreased,"All liraglutide doses were superior to placebo (P < 0.0001),", HbA1c level at 26 weeks , Placebo plus glimepiride , Liraglutide (1.8 mg) plus glimepiride ,0,
